Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 5Breast 3Lymphoid 2Dermatologic 2Sarcoma 1Genitourinary 1

Conditions

Sarcoma 4Melanoma 4Breast Neoplasms 3Urinary Bladder Neoplasms 2Osteosarcoma 2Gliosarcoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 11Nivolumab 4Erlotinib Hydrochloride 3Docetaxel 3Cetuximab 3Capecitabine 3tislelizumab 2spartalizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Gemcitabine 2Filgrastim 2Cyclophosphamide 2tremelimumab 1sargramostim 1ribociclib 1poly ICLC 1pexidartinib 1mirabegron 1futibatinib 1etoposide phosphate 1entinostat 1durvalumab 1ciforadenant 1cemiplimab 1capivasertib 1bempegaldesleukin 1avelumab 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × poly ICLC × Sarcoma × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡